Isolated hypoxic perfusion with mitomycin C in patients with advanced pancreatic cancer

European Journal of Surgical Oncology

Volumn 24, Issue 6, 1998, Pages 542-547

  Lorenz, Matthias ^a,b   Petrowsky, Henrik ^a   Heinrich, Stefan ^a   Janshon, Gunnar ^a   Staib Sebler, Elsbeth ^a   Poloczek, Yvonne ^a   Gog, Christiane ^a   Oremek, Gerhard ^a   Encke, Albrecht ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Advanced pancreatic carcinoma; Isolated hypoxic perfusion; Mitomycin C; Regional chemotherapy

Indexed keywords

MITOMYCIN C;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; DIARRHEA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; LIVER TOXICITY; MALE; NAUSEA; NEPHROTOXICITY; OXYGEN TISSUE LEVEL; PANCREAS CANCER; PANCREAS DISEASE; PRIORITY JOURNAL; RECURRENT CANCER; REGIONAL PERFUSION; VOMITING;

EID: 0031649999     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0748-7983(98)93572-7     Document Type: Article

References (23)

1. Brennan MF, Kinsella TJ, Casper ES. Cancer of the pancreas. In: DeVita VT Jr, Hellmann S, Rosenberg SA (eds). Cancer: Principles & Practice of Oncology (4th edn). Philadelphia: JB Lippincott, 1993: 849-82.
2. Moore M. Activity of gemcitabine in patients with advanced pancreatic carcinoma. Cancer 1996; 78: 633-8.
3. Ahlgren JD. Chemotherapy for pancreatic carcinoma. Cancer 1996; 78: 654-63.
4. Crooke ST. Bradner WT. Mitomycin C: a review. Cancer Treat Rev 1976; 3: 121-39.
5. Kennedy KA, Siegfried JM, Sartorelli AC, Tritton TR. Effects of anthracyclines on oxygenated and hypoxic tumor cells. Cancer Res 1983; 43: 54-9.
6. Teicher BA, Lazo JS, Sartorelli AC. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 1981; 41: 73-81.
7. Hafslröm L, Ihse I, Jönsson P-E, Lunderquist A, Stridbeck H. Intraarterial 5-FU infusion with or without oral testolactone treatment in irresectable pancreatic cancer. Acta Chir Scand 1980; 146: 445-4.
8. Smith R, Gazet JC. Intra-arterial chemotherapy for patients with inoperable carcinoma of the pancreas. Ann R Coll Surg Engl 1980; 62: 208-12.
9. Klein ES, Ben-Ari GY, Papa MZ, Adar R, Bass A. Vascular complications of abdominal perfusion and aortic stop-flow infusion. J Surg Oncol 1996; 61: 17-9.
10. Shimamura Y, Gunvén P, Ishii M, Abe K. Temporary redistribution of hepatic or pancreatic blood flow by vascular occluders during intra-arlerial chemotherapy for carcinoma of the liver or pancreas. Surg Gynecol Obstet 1993; 177: 617-9.
11. Gansauge F, Link KH, Rilinger N, Kunz R, Beger HG. Regionale chemotherapie beim fortgeschrittenen pankreaskarzinom. Med Klin 1995; 9: 501-5.
12. Link KH, Gansauge F. Pillasch J, Rilinger N, Büchler M, Beger HG. Regional chemotherapy of advanced nonresectable and of resected pancreatic cancer via celiac axis infusion. Dig Surg 1994; 11: 414-9.
13. Muchmore JH, Preslan JE, George WJ. Regional chemotherapy for inoperable pancreatic carcinoma. Cancer 1996; 78: 664-73.
14. Karni T, Klein E, Papa MZ, Lin M, Koler M, Ben-Ari G. Total abdominal ischemic perfusion with chemotherapeutic drugs for intra-abdominal cancer. Reg Cancer Treat 1993; Suppl: 28.
15. 14C-labeled mitomycin C. J Surg Res 1995; 59: 415-9.
16. Arredondo MA, Thomford NR, Chaudhuri B, Chaudhuri PK. Pharmacokinetics and tissue uptake of mitomycin C in isolated perfusion of pancreas. J Surg Res 1989; 46: 445-9.
17. Aigner KR, Gailhofer S. Regional chemotherapy for nonresectable, locally metastasized pancreatic cancer-four studies including 164 cases. Reg Cancer Treat 1993; Suppl. 2.
18. Haskell CM. Cancer Treatment (4th edn). Philadelphia: WB Saunders, 1995; 1164-9.
19. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
20. Simon R. How large should a phase II trial of a new drug be? Cancer Treat Rep 1987; 71: 1079-85.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-62.
22. Schilcher RB, Young JD, Ratanatharathorn V, Karanes C, Baker LH. Clinical pharmacokinetics of high-dose mitomycin C. Cancer Chemother Pharmacol 1984; 13: 186-90.
23. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983; 62: 14-31.